Form 4: BiomX Director Sells Shares, Warrants After Preferred Stock Conversion

BiomX Inc. director and 10% owner Reuven Yeganeh reported converting preferred stock into common shares and subsequently selling common stock and warrants in private transactions.

Summary

• Reuven Yeganeh, a director and 10% owner of BiomX Inc., converted Series Y Convertible Preferred Stock into common stock.
• On March 16, 2026, 450,000 shares of common stock were acquired through conversion at $2.00 per share and then sold at $5.00 per share.
• On March 17, 2026, an additional 530,000 shares of common stock were acquired through conversion at $2.00 per share and then sold at $5.00 per share.
• On March 16, 2026, Mr. Yeganeh also sold 1,300,000 common stock purchase warrants at $5.00 per warrant share, 2,000,000 warrants at $5.24 per warrant share, and 1,700,000 warrants at $4.76 per warrant share in private transactions.
• The reported securities are indirectly owned by Pyu Pyu Capital, LLC, where Mr. Yeganeh is the sole member.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive for the insider due to profitable sales, but potentially neutral to slightly negative for the company's stock sentiment given the insider selling activity.

Positives

• The common stock acquired through conversion was sold at $5.00 per share, significantly higher than the $2.00 conversion price, indicating a profitable transaction for the reporting person.
• The sale of warrants at prices ranging from $4.76 to $5.24 per warrant share also represents a monetization event for the reporting person.

Negatives

• The sale of a significant number of common shares and warrants by a director and 10% owner could be interpreted as a reduction in insider confidence or a move to diversify holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, are closely watched by the market as they can signal management's perception of the company's value. While these specific transactions relate to a director's personal investment strategy, they occur within the broader biotechnology industry, where capital allocation and investor sentiment are critical. Competitors in the phage therapy or microbiome space would also see their insider activity scrutinized similarly.

Related Party Transactions

• The reported securities are directly owned by Pyu Pyu Capital, LLC, and may be deemed beneficially owned by Reuven Yeganeh as the sole member of Pyu Pyu.
• Reuven Yeganeh disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares and warrants by a director and 10% owner could be perceived negatively, potentially signaling a lack of confidence or a desire to reduce exposure, which might influence investor sentiment.
• Company: The transactions themselves do not directly impact the company's operations or financial health, but the market's reaction to insider selling could affect its stock price.

Key Dates

Recommendation

While the insider's transactions were profitable, the sale of a substantial number of shares and warrants by a director and 10% owner could be interpreted as a signal of reduced confidence or a strategic portfolio adjustment. This insider selling activity, despite being profitable for the individual, might introduce a degree of uncertainty for other investors. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future insider activity and company developments before making further investment decisions.

Keywords

BiomX Inc., PHGE, Reuven Yeganeh, Insider Trading, Form 4, Stock Sale, Warrant Sale, Preferred Stock Conversion, Director, 10% Owner, Pyu Pyu Capital LLC